Mike Ford
AstraZeneca
4 Papers
Mike Ford is an academic researcher from AstraZeneca. The author has contributed to research in topics: Microbiome & Retrospective cohort study. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
Engraftment of Bacteria after Fecal Microbiota Transplantation Is Dependent on Both Frequency of Dosing and Duration of Preparative Antibiotic Regimen
Vancheswaran Gopalakrishnan,Elizabeth Ashley Dozier,Matthew S. Glover,Steven Novick,Mike Ford,Christopher Morehouse,Paul Warrener,Carolina S. Caceres,Sonja Hess,Bret R. Sellman,Taylor S. Cohen +10 more
- 29 Jun 2021
TL;DR: In this article, the authors used 16S ribosomal RNA (rRNA) sequencing and liquid chromatography-mass spectrometry (LC-MS) profiling of fecal samples.
25
Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease
Iskandar Idris,Ruiqi Zhang,Jil B Mamza,Mike Ford,Tamsin Morris,Amitava Banerjee,Kamlesh Khunti +6 more
TL;DR: To confirm the reno‐protective effects of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors on the onset and progression of chronic kidney disease (CKD) in routine clinical practice, a comparison study is conducted.
7
Differences in Cardiovascular and Renal Outcomes Between Sodium Glucose Co-Transporter-2 and Dipeptidyl Peptidase-4 Inhibitors Among Type 2 Diabetes Patients: A Real-World, Retrospective Cohort Study
Iskandar Idris,Ruiqi Zhang,Jil Billy Mamza,Mike Ford,Tamsin Morris,Amitava Banerjee,Kamlesh Khunti +6 more
TL;DR: SGLT 2i were associated with reduced risk of all–cause mortality and hospitalisation for HF and CKD compared with DPP4–i, highlighting the need to introduce SGLT2i early in the management of T2D patients.
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Iskandar Idris,Ruiqi Zhang,Ruiqi Zhang,Jil Billy Mamza,Mike Ford,Tamsin Morris,Amitava Banerjee,Kamlesh Khunti +7 more
TL;DR: In this paper, the authors found that SGLT2is were associated with a reduced risk of all-cause mortality and hospitalization for heart failure (HF) and chronic kidney disease (CKD) compared with DPP4is.